The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer

Cancer Research

Volumn 58, Issue 13, 1998, Pages 2766-2771

  Heimann, Ruth ^a,b   Ferguson, Donald J ^a   Hellman, Samuel ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; ONCOPROTEIN; PROTEIN NM23; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CORRELATION FUNCTION; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; ONCOGENE; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MICROCIRCULATION; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEOSIDE-DIPHOSPHATE KINASE; TRANSCRIPTION FACTORS;

EID: 0032127341     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Ries, L. A., Miller, B. A., Hankey, B. F., Kosary, C. L., Harras, A., and Edwards, B. K. SEER cancer statistics review, 1973-1991: Tables Graphs. National Cancer Institute, NIH Publication No. 94-2789. Bethesda, MD: NIH, 1994.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women, Lancet, 339: 71-85, 1992.
3. Fisher, B., Dignam, J., Wolmark, N., DeCillis, A., Emir, B., Wickerman, D. L., Bryant, J., Dimitrov, N. V., Abramson, N., Atkins, J. N., Shibata, H., Deschenes, L., and Margolese, R. G. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor positive breast cancer. J. Natl. Cancer Inst., 89: 1673-1682, 1997.
4. Rosen, P. R., Groshen, S., Saigo, P. E., Kinne, D. W., and Hellman, S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J. Clin. Oncol., 7: 355-366, 1989.
5. Quiet, C. A., Ferguson, D. J., Weichselbaum, R. R., and Hellman, S. Natural history of node-negative breast cancer a study of 826 patients with long-term follow up. J. Clin. Oncol., 13: 1144-1151, 1995.
6. Killion, J. J., and Fiddler, I. J. The biology of tumor metastasis. Semin. Oncol., 16: 105-115, 1989.
7. Kohn, E. C., and Liotta, L. A. Invasion and metastasis: new approaches to an old problem. Oncology, 7: 47-62, 1993.
8. Stracke, M. L., and Liotta, L. A. Molecular mechanism of tumor cell metastasis. In: J. Mendelsohn, P. Howley, A. Israel, and L. A. Liotta (eds.), The Molecular Basis of Cancer, pp. 233-247. Philadelphia: W. B. Saunders Company, 1995.
9. Steeg, P. S., Cohn, K. H., and Leone, A. Tumor metastasis and nm23: current concepts. Cancer Cells, 3: 257-262, 1991.
10. Steeg, P. S., De La Rosa, A., Flatow, U., MacDonald, N. J., Benedict, M., and Leone, A. nm23 and breast cancer metastasis. Breast Cancer Res. Treat., 25: 175-187, 1993.
11. MacDonald, N. J., De La Rosa, A., and Steeg, P. S. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur. J. Cancer, 31A: 1096-1100, 1995.
12. Steeg, P. S., Bevilacqua, G., Kopper, L., Thorgeirsson, U. P., Talmadge, J. E., Liotta, L. A., and Sobel, M. E. Evidence for a novel gene associated with low tumor metastatic potential. J. Natl. Cancer Inst., 80: 200-204, 1988.
13. Rosengard, M. A., Krutzsch, H. C., Shearn, A., Biggs, J. R., Barker, E., Margulies, I. M. K., King, C. R., Liotta, L. A., and Steeg, P. S. Reduced Nm23/Awd protein in tumor metastasis and aberrant Drosophila development. Nature (Lond.), 342: 177-180, 1989.
14. Stahl, J. A., Leone, A., Rosengard, A. M., Porter, L., King, C. R., and Steeg, P. S. Identification of a second nm23 gene, nm23-H2. Cancer Res., 51: 445-449, 1992.
15. MacDonald, N. J., DeLaRosa, A., Benedict, M. A., Freije, J. M. P., Krutsch, H., and Steeg, P. S. A serine phosphorylation of nm23, and not its nucleoside diphosphate kinase activity, correlates with suppression of tumor metastatic potential. J. Biol. Chem., 34: 25780-25789, 1993.
16. Leone, A., Flatow, U., VanHoutte, K., and Steeg, P. Transfection of human nm23H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization, and enzymatic activity. Oncogene, 8: 2325-2333, 1993.
17. Tokunaga, Y., Urano, T., Furukawa, K., Kondo, H., Kanematsu, T., and Shiku, H. Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int. J. Cancer, 55: 66-71, 1993.
18. Kantor, J. D., McCormick, B., Steeg, P. S., and Zetter, B. R. Inhibition of cell motility after nm23 transfection of human and murine tumor cells. Cancer Res., 53: 1971-1973, 1993.
19. Bevilacqua, G., Sobel, M. E., Liotta, L. A., and Steeg, P. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res., 49: 5185-5190, 1989.
20. Hennessy, C., Henry, J. A., May, F. E. B., Westley, B. R., Angus, B., and Lennard, T. W. J. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. J. Natl. Cancer Inst., 83: 281-285, 1991.
21. Okubo, T., Inokuma, S., Takeda, S., Itoyama, S., Kinoshita, K., and Sugawara, I. Expression of nm23-H1 gene product in thyroid, ovary, and breast cancer. Cell Biophys., 26: 205-213, 1995.
22. Duenas-Gonzales, A., Abad-Hernandez, M. M., Garcia-Mata, J., Paz-Bouza, J. I., Cruz-Hernandez, J. J., and Gonzales-Sarmiento, R. Analysis of nm23-H1 expression in breast cancer. Correlation with p53 expression and clinicopathologic findings. Cancer Lett., 101: 137-142, 1996.
23. Royds, J. A., Stephenson, T. J., Rees, R. C., Shorthouse, A. J., and Silcocks, P. B. Nm23 protein expression in ductal carcinoma in situ and invasive human breast carcinoma, J. Natl. Cancer Inst., 85: 727-731, 1993.
24. Barnes, R., Massood, S., Barker, E., Rosengard, A. M., Coggin, D. L., Crowell, T., King, C. R., Porter-Jordan, K., Wargortz, E. S., Liotta, L. A., and Steeg, P. S. Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am. J. Pathol., 139: 245-250, 1991.
25. Toulas, C., Mihura, J., de Balincourt, C., Marques, B., Marek, E., Soula, G., Roche, H., and Favre, G. Potential prognostic value in human breast cancer on cytosolic Nme1 protein detection using an original hen specific antibody. Br. J. Cancer, 73: 630-635, 1996.
26. Folkman, J., and Klagsburn, M. Angiogenic factors. Science (Washington DC), 235: 442-443, 1987.
27. Folkman, J. Clinical application of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.
28. Folkman, J. Tumor angiogenesis. In: J. Mendelsohn, P. Howley, A. Israel, and L. A. Liotta (eds.), The Molecular Basis of Cancer, pp. 206-224. Philadelphia: W. B. Saunders Company, 1995.
29. Liotta, L. A., Kleinerman, J., and Saidel, G. M. Quantitative relationship of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor transplantation. Cancer Res., 34: 997-1004, 1974.
30. Liotta, L. A., Kleinerman, J., and Saidel, G. M. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res., 36: 889-894, 1976.
31. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., and Gasparini, G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst., 84: 1875-1887, 1992.
32. Gasparini, G., Weidner, N., Bevilacqua, P., Maluta, S., Dalla Palma, P., Caffo, O., Barbareschi, M., Boracchi, P., Marubini, E., and Pozza, F. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. Clin. Oncol., 12: 454-466, 1994.
33. Heimann, R., Ferguson, D., Powers, C., Recant, W. M., Weichselbaum, R. R., and Hellman, S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J. Natl. Cancer Inst., 88: 1764-1769, 1996.
34. Heimann, R., Ferguson, D., Gray, S., and Hellman, S. Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis. Breast Cancer Res. Treat., in press, 1998.
35. Ferguson, D. J., Meier, P., Karisson, T., Dawson, P. J., Straus, F. H., and Lowenstein, F. E. Staging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy. J. Am. Med. Assoc., 248: 1337-1341, 1982.
36. Hellman, S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J. Clin. Oncol., 12: 2229-2234, 1994.
37. Heimann, R., Ferguson, D., Powers, C., and Hellman, S. Angiogenesis and estrogen receptor in young women with breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 39(2S): 136, 1997.
38. Heimann, R., Ferguson, D., Powers, C., Suri, D., Weichselbaum, R. R., and Hellman, S. Race and clinical outcome in breast cancer in a series with long follow-up evaluation. J. Clin. Oncol., 15: 2329-2337, 1997.
39. Fisher, E. R., Redmond, C., and Fisher, B. Histologic grading of breast cancer. Pathol. Annu., 15: 239-251, 1980.
40. Miller, R. T. Immunohistochemistry in the community practice of pathology. Lab. Med., 22: 527-532, 1991.
41. Gasparini, G., and Harris, A. L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. Clin. Oncol., 13: 765-782, 1995.
42. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
43. Weidner, N., and Folkman, J. Tumor vascularity as a prognostic factor in cancer. PPO Updates, 11: 1-24, 1997.
44. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
45. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
46. Leone, A., Flatow, U., King, C. R., Sandeen, M. A., Margulies, M. K., Liotta, L. A., and Steeg, P. S. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell, 65: 25-35, 1991.
47. Liotta, L. A., Stetler-Stevenson, W., and Steeg, P. S. Metastasis suppressor genes. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Imp. Adv. Oncol., pp. 85-100. Philadelphia: Lippincott-Raven, 1991.
48. Liotta, L. A., and Steeg, P. S. Clues to the function of Nm23 and Awd proteins in development, signal transduction and tumor metastasis provided by studies of Dictyostelium discoideum. J. Natl. Cancer Inst., 82: 1170-1172, 1990.
49. Howlett, A. R., Petersen, O. W., Steeg, P., and Bissell, M. J. A novel function for the nm23-H1 gene: overexpression in human breast carcinoma cell leads to the formation of basement membrane and growth arrest. J. Natl. Cancer Inst., 86: 1838-1844, 1994.
50. Hirayama, R., Sawai, S., Takagi, Y., Mishima, Y., Kimura, N., Shimada, N., Esaki, Y., Kurashima, C., Utsuyama, M., and Hirokawa, K. Positive relationship between expression of anti-metastatic factor (nm23 gene product or nucleoside diphosphate kinase) and good prognosis in human breast cancer. J. Natl. Cancer Inst., 83: 1249-1250, 1991.
51. Sastre-Garau, X., Lacombe, M. L., Jouve, M., Veron, M., and Magdelenat, H. Nucleoside diphosphate-kinase/nm23 expression in breast cancer: lack of correlation with lymph-node metastasis. Int. J. Cancer, 50: 533-538, 1992.
52. Sawan, A., Lascu, I., Veron, M., Anderson, J. J., Wright, C., Horne, C. H. W., and Angus, B. NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study. J. Pathol., 172: 27-34, 1994.
53. Kapranos, N., Karaiossifidi, H., Kouri, E., and Vasilaros, S. Nm23 expression in breast ductal carcinomas: a ten year follow-up in a uniform group of node-negative breast cancer patients. Anticancer Res., 16: 3987-3990, 1996.
54. Freije, J. M. P., MacDonald, N. J., and Steeg, P. S. Differential gene expression in tumor metastasis: nm23. Curr. Top. Microbiol. Immunol., 213: 215-232, 1996.
55. Heimann, R., and Hellman, S. Aging, progression, and phenotype in breast cancer, J Clin. Onc. (In press) 1998.
56. Heimann, R., Ferguson, D., Recant, W. M., and Hellman, S. Breast cancer metastatic phenotype as predicted by histologic tumor markers. Cancer J. Sci. Am., 4: 224-229, 1997.
57. Hanahan, D., and Folkman, J. Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.